Tuberculosis BCG vaccine found ineffective against COVID-19 in healthcare workers
An international trial has investigated the potential immune-boosting effects of the tuberculosis BCG vaccine against COVID-19. The results show that the risk of developing the disease during the first six months after vaccination was not reduced in participants as originally hoped for. Nearly 4,000 healthcare workers took part in the BRACE trial across 36 sites from five countries, including the Germans Trias Hospital. Researchers from an IGTP tuberculosis research group were involved in the development of the study, which has been published in the New England Journal of Medicine.